tradingkey.logo


tradingkey.logo


Apellis Pharmaceuticals Inc

APLS
24.970USD
-0.190-0.76%
終倀 12/26, 16:00ET15分遅れの株䟡
3.16B時䟡総額
70.44盎近12ヶ月PER


Apellis Pharmaceuticals Inc

24.970
-0.190-0.76%

詳现情報 Apellis Pharmaceuticals Inc 䌁業名

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Apellis Pharmaceuticals Incの䌁業情報


䌁業コヌドAPLS
䌚瀟名Apellis Pharmaceuticals Inc
䞊堎日Nov 09, 2017
最高経営責任者「CEO」Francois (Cedric)
埓業員数705
蚌刞皮類Ordinary Share
決算期末Nov 09
本瀟所圚地100 Fifth Avenue
郜垂WALTHAM
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号02451
電話番号16179775700
りェブサむトhttps://apellis.com/
䌁業コヌドAPLS
䞊堎日Nov 09, 2017
最高経営責任者「CEO」Francois (Cedric)

Apellis Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
92.58K
-5.12%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
16.48K
--
Ms. Keli Walbert
Ms. Keli Walbert
Independent Director
Independent Director
9.09K
--
Ms. Stephanie Monaghan O'Brien, J.D.
Ms. Stephanie Monaghan O'Brien, J.D.
Independent Director
Independent Director
955.00
-86.25%
Mr. Niel Carnahan
Mr. Niel Carnahan
Investor Contact
Investor Contact
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
92.58K
-5.12%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
事業別USD
䌚瀟名
収益
比率
SYFOVRE
150.63M
84.39%
EMPAVELI
20.76M
11.63%
Licensing and other revenue
7.11M
3.98%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
SYFOVRE
150.63M
84.39%
EMPAVELI
20.76M
11.63%
Licensing and other revenue
7.11M
3.98%

株䞻

曎新時刻: Mon, Nov 17
曎新時刻: Mon, Nov 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Wellington Management Company, LLP
10.87%
Morningside Venture Investments, Ltd.
10.12%
Avoro Capital Advisors LLC
9.66%
The Vanguard Group, Inc.
7.88%
Morgan Stanley & Co. LLC
7.26%
他の
54.21%
株䞻統蚈
株䞻統蚈
比率
Wellington Management Company, LLP
10.87%
Morningside Venture Investments, Ltd.
10.12%
Avoro Capital Advisors LLC
9.66%
The Vanguard Group, Inc.
7.88%
Morgan Stanley & Co. LLC
7.26%
他の
54.21%
皮類
株䞻統蚈
比率
Investment Advisor/Hedge Fund
45.40%
Investment Advisor
23.60%
Hedge Fund
17.53%
Research Firm
10.49%
Corporation
10.12%
Individual Investor
3.78%
Bank and Trust
2.44%
Sovereign Wealth Fund
1.87%
Private Equity
1.84%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
652
131.04M
116.63%
+4.47M
2025Q3
672
126.71M
118.50%
-5.66M
2025Q2
699
132.30M
122.54%
+1.89M
2025Q1
718
128.54M
117.00%
-18.47M
2024Q4
706
128.71M
111.21%
+6.68M
2024Q3
691
120.87M
110.47%
+2.88M
2024Q2
680
117.66M
106.02%
+2.29M
2024Q1
677
115.10M
106.81%
-13.69M
2023Q4
648
115.71M
108.26%
-132.41K
2023Q3
622
115.96M
104.32%
-1.36M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Wellington Management Company, LLP
8.98M
7.11%
-3.33M
-27.04%
Jun 30, 2025
Morningside Venture Investments, Ltd.
12.81M
10.14%
--
--
Mar 31, 2025
Avoro Capital Advisors LLC
12.22M
9.68%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
10.14M
8.03%
+24.39K
+0.24%
Jun 30, 2025
Morgan Stanley & Co. LLC
7.57M
6%
-524.46K
-6.48%
Jun 30, 2025
Deep Track Capital LP
7.00M
5.54%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
4.34%
+49.97K
+0.92%
Jun 30, 2025
AQR Capital Management, LLC
5.98M
4.73%
+1.90M
+46.57%
Jun 30, 2025
Jennison Associates LLC
2.66M
2.11%
+184.29K
+7.44%
Jun 30, 2025
State Street Investment Management (US)
3.56M
2.82%
-378.68K
-9.61%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Simplify Health Care ETF
1.92%
Virtus LifeSci Biotech Products ETF
1.78%
ALPS Medical Breakthroughs ETF
1.17%
State Street SPDR S&P Biotech ETF
0.88%
First Trust Health Care Alphadex Fund
0.83%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
ProShares Ultra Nasdaq Biotechnology
0.33%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
Invesco Nasdaq Biotechnology ETF
0.26%
iShares Biotechnology ETF
0.2%
詳现を芋る
Simplify Health Care ETF
比率1.92%
Virtus LifeSci Biotech Products ETF
比率1.78%
ALPS Medical Breakthroughs ETF
比率1.17%
State Street SPDR S&P Biotech ETF
比率0.88%
First Trust Health Care Alphadex Fund
比率0.83%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.54%
ProShares Ultra Nasdaq Biotechnology
比率0.33%
First Trust Small Cap Growth AlphaDEX Fund
比率0.27%
Invesco Nasdaq Biotechnology ETF
比率0.26%
iShares Biotechnology ETF
比率0.2%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Apellis Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


Apellis Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。
Wellington Management Company, LLPは8.98M株を保有しおおり、これは党䜓の7.11%に盞圓したす。
Morningside Venture Investments, Ltd.は12.81M株を保有しおおり、これは党䜓の10.14%に盞圓したす。
Avoro Capital Advisors LLCは12.22M株を保有しおおり、これは党䜓の9.68%に盞圓したす。
The Vanguard Group, Inc.は10.14M株を保有しおおり、これは党䜓の8.03%に盞圓したす。
Morgan Stanley & Co. LLCは7.57M株を保有しおおり、これは党䜓の6.00%に盞圓したす。

Apellis Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は䜕ですか


Apellis Pharmaceuticals Incの株䞻タむプ䞊䜍3皮は、
Wellington Management Company, LLP
Morningside Venture Investments, Ltd.
Avoro Capital Advisors LLC

Apellis Pharmaceuticals IncAPLSの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Apellis Pharmaceuticals Incの株匏を保有しおいる機関は652瀟あり、保有株匏の総垂堎䟡倀は玄131.04Mで、党䜓の116.63%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-1.87%増加しおいたす。

Apellis Pharmaceuticals Incの最倧の収益源は䜕ですか


FY2025Q2においお、 SYFOVRE郚門がApellis Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は150.63Mで、党収益の84.39%を占めおいたす。
KeyAI
î™